An observational study in Respiratory Distress Syndrome, Adult and Septic Shock, sponsored by University Hospital Tuebingen. Completed at 1 site in Germany. Per ClinicalTrials.gov, last updated 2018-04-24.
Sponsored by University Hospital Tuebingen · Observational
57 patients with Adult Respiratory Distress Syndrome (ARDS) requiring Extracorporeal membrane oxygenation (ECMO) therapy were analyzed retrospectively. 28 patients had received immunglobulin M-enriched immunoglobulin therapy (IVIG); 29 patients did not receive IVIG therapy.
These patients were analyzed regarding length of stay in intensive care unit (LOS ICU), length of stay (LOS) in hospital and regarding mortality.
57 patients with ARDS requiring ECMO therapy were analyzed retrospectively. 28 patients had received IgM-enriched immunoglobulin therapy (IVIG); 29 patients did not receive IVIG therapy.
Patient characteristics, like Acute Physiology And Chronic Health Evaluation (APACHE) and Sepsis-related organ failure assessment (SAPS) Score, preexisting diseases, origin of infection, duration of ECMO therapy were analyzed in these patients.
These patients were further analyzed regarding LOS ICU, LOS in hospital and regarding mortality.
1,597 studies on the registry are indexed under Respiratory Distress Syndrome; 312 are open to participants now.
This study's enrollment of 57 is below the median of 100 across 540 observational studies indexed under Respiratory Distress Syndrome.
Browse Respiratory Distress Syndrome studies →University Hospital Tuebingen is the lead sponsor of 476 studies on the registry; 104 are open to participants now.
Counted across the registry records on this site, refreshed daily.
ARDS patients treated by ECMO in the anesthesiological ICU of University Hospital Tuebingen between january 2012 and december 2015
Exclusion Criteria:
ARDS patients with septic shock requiring ECMO therapy were treated for 3 days by IgM-enriched Immunoglobulin
Drug: IgM enriched Immunoglobulins
ARDS patients with septic shock requiring ECMO therapy were NOT treated by IgM-enriched Immunoglobulin
Treatment for 3 days
Also known as: Pentaglobin, Biotest Pharma GmbH Germany; Code 170a/90
Mortality
Death during ICU therapy
Time frame: during ICU treatment, up to 28 days
lengh of stay (LOS ICU)
lengh of stay on ICU in days
Time frame: up to 60 days
Plan to share: Undecided
This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome→
University Hospital Tuebingen